Citations

Clear

2429 citation(s) found for "Shah, SS".

Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.
US multicenter outcomes of endoscopic ultrasound-guided gallbladder drainage with lumen-apposing metal stents for acute cholecystitis
David, Yakira , Kakked, Gaurav, Confer, Bradley , Shah, Ruchit N. , Khara, Harshit S. , Diehl, David L. , Krafft, Matthew , Shah-Khan, Sardar M. , Nasr, John , Benias, Petros C. , Muniraj, Thiruvengadam , Aslanian, Harry R., Chahal, Prabhleen , Rodriguez, John , DuBroff, Jason, Latour, Rabi De, Khanna, Lauren , Haber, Gregory , Hoerter, Nicholas A. , Pandey, Nishi , Bakhit, Mena , Kowalski, Thomas E., Loren, David E. , Chiang, Austin , Schlachterman, Alexander , Nieto, Jose , Ichkhanian, Yervant , Khashab, Mouen A. , Halabi, Maan El , Kwon, Richard S. , Hernandez-Lara, Ariosto, Poneros, John M., Sethi, Amrita, Gonda, Tamas A. , Kushnir, Vladimir , Cosgrove, Natalie , Mullady, Daniel , Al-Shahrani, Abdullah , Buscaglia, Jonathan M. , Bucobo, Juan Carlos , Rolston, Vineet S. , Kedia, Prashant , Kasmin, Franklin, Kumta, Nikhil A. , DiMaio, Christopher J. , Krafft, Matthew Richard , Trindade, Arvind J. , Adler, Douglas G. , Tzimas, Demetrios J. , Goodman, Adam J. , Nieto, José , Deshmukh, Ameya A. , Prabhu, Anoop , Storm, Andrew C. , Berzin, Tyler M. , Sethi, Amrita , D'Souza, Lionel S. , Nagula, Satish

Mayo Clinic

Endoscopy International Open | January 13, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2495-5542 | PMID 39958659 Get It

AbstractEUS-guided gallbladder drainage (EUS-GBD) using lumen apposing metal stents (LAMS) has excellent technical and short-term clinical success for acute cholecystitis (AC). The goals of this study were to determine the long-term clinical outcomes and adverse events (AEs) of EUS-GBD with LAMS.A multicenter, retrospective study was conducted at 18 US tertiary care institutions. Inclusion criteria: any AC patient with attempted EUS-GBD with LAMS and minimum 30-day post-procedure follow-up. Long-term clinical success was defined as absence of recurrent acute cholecystitis (RAC) > 30 days and long-term AE was defined as occurring > 30 days from the index procedure.A total of 109 patients were included. Technical success was achieved in 108 of 109 (99.1%) and initial clinical success in 106 of 109 (97.2%). Long-term clinical success was achieved in 98 of 109 (89.9%) over a median follow-up of 140 days (range 30–1188). On multivariable analysis (MVA), acalculous cholecystitis (odds ratio [OR] 15.93, 95% confidence interval [CI] 1.22–208.52, P = 0.04) and the occurrence of a LAMS-specific AE (OR 63.60, 95% CI 5.08–799.29, P <0.01) were associated with RAC. AEs occurred in 38 of 109 patients (34.9%) at any time, and in 10 of 109 (9.17%) > 30 days from the index procedure. Most long-term AEs (7 of 109; 6.42%) were LAMS-specific. No technical or clinical factors were associated with occurrence of AEs. LAMS were removed in 24 of 109 patients (22%). There was no difference in RAC or AEs whether LAMS was removed or not.EUS-GBD with LAMS has a high rate of long-term clinical success and modest AE rates in patients with AC and is a reasonable destination therapy for high-risk surgical candidates.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Wixner, Jonas , Polydefkis, Michael , Ueda, Mitsuharu , Bender, Shaun, Jay, Patrick Y. , Yureneva, Elena, group, patisiran Global OLE study, Vita, Giuseppe, Rizzo, Vincenzo , Wiesman, Janice F. , Lau, Vincent , DeLong, Douglas, May, John J., Delmont, Émilien , Pouget, Jean, Grapperon, Aude‐Marie , Campana-Salort, Emmanuelle, Coutinho, Conceição de Azevedo, Campos, Catarina Falcão de , Coelho, Teresa , Reis, Antonio Hipólito, Pérez, Javier Martínez , Silva, Ana Martins da, Alves, Cristina , Cardoso, Márcio , Valdrez, Kátia, Monte, Julia R, Novais, Marta , Guimarães, Nádia, Cardoso, Inês , Freitas, Mónica, Ferreira, Natália , Kuzume, Daisuke , Morimoto, Yuko, Gauvain, Clément , Migaud-Chervy, Maria-Claire, Deplanque, Dominique , Jozefowicz, Elsa, Théaudin-Saliou, Marie, Cauquil-Michon, Cécile, Labeyrie, Céline , Not, Adeline , Lecoq, Anne-Lise , Stephant, Maeva, Echaniz‐Laguna, Andoni , Becquemont, Laurent , Beaudonnet, Guillemette , Eliahou, Ludivine , Slama, Michel , Signaté, Aïssatou , Darche, Paola, Grimaud, Jérôme, Berthelot, Emeline, Inamo, Jocelyn , Gendre, Thierry , Arrouasse, Raphaele , Ernande, Laura , Salhi, Hayet, Choumert, Ariane , Charlin, Cyril, Megelin, Thomas, Brannagan, Thomas H., Tsang, Steven, Wajnsztajn, Fernanda, Shije, Jeffrey, Ulane, Christina, Kleyman, Inna , Weimer, Louis H., Cioroiu, Comana , Kleopa, Kleopas A. , Zamba‐Papanicolaou, Eleni , Tada, Satoshi , Nagai, Masahiro , Ando, Rina, Yamanishi, Yuki , Overcash, J. Scott , Green, Sinikka, Coskun, Derya J, Manos, Paul S. , Zepeda, Karla A, O’Riordan, William, Cortese, Andrea , Bernardo, Daniela, Paolantonio, Andrea Di , Guglielmino, Valeria , Kristen, Arnt V. , Nagel, Christian , Siepen, Fabian aus dem , Hein, Selina , Campistol, Josep M. , Marín, Lida María Rodas, Pelicano, Josep Miquel Blasco, Dávila, Lucía Galán, Cordoba, Vanesa Pytel, Sola, A. Guerrero, Feijoo, Julián García, Isla, Leopoldo Pérez de , Moreira, Carolina Lavigne , Marques, Vanessa Daccach , Beamud, Francisco Muñoz, Borrachero, Cristina, Sanz, Mónica, Oliver, E, Moreno, Juan González, Martinez, J. Michael, Descals, Cristina, Usón, Mercedes, Vega, Francisco Jose, Figuerola, Antoni, Montalà, Carles, Abreu, Aline França de , Silva, Moises Dias da, Rosa, Renata Gervais de Santa, Berensztejn, Amanda Cardoso, Guedes, Mariana de Andrade, Lautre, Andrea, Orellana, Lucas, Briseño, Maria Alejandra González-Duarte, Parra, David Rivera de la, Reyes, Jose Pablo Hernandez, Alba, Maria del Mar Saniger, Parman, Yeşim , Serbest, Nail Güven , Durmuş, Hacer , Karamürsel, Saçit , Elitok, Ali, Inan, Nermin G Sirin, Altinkurt, Emre, Polydefkis, Michael, Allen, Adriane C, Chaudhry, Vinay , Jarrett, R. J., Bressler, Neil M. , Khoshnoodi, Mohammad , Lui, Alvin T, Chung, Tae , Vista, Geno, Shah, Syed Mahmood , Hamaguchi, Hirotoshi , Oda, Tetsuya , Shimomura, Masahiro, Kim, Hee Jin, Misumi, Yohei , Nomura, Toshiya , Tateishi, Takahisa , Mauricio, Elizabeth A. , Dimberg, Elliot L., Fonder, Amie , Hobbs, Miriam, Dyck, P. James B. , Leung, Nelson , Hwa, Yi L. , Kapoor, Prashant , Kumar, Shaji , Dingli, David , Gove, Linde E., Dalia, Samir , Croy, David, Holding, Tim, Gorevic, Peter D., Su, Jen-Jen , Lin, Chao-Wen, Ajroud‐Driss, Senda , Sufit, Robert , Li, John-Michael, Freimer, Miriam , LoRusso, Samantha, Aso, Yasuhiro , Kim, Byoung‐Joon , Kim, JuHyeon, Jeon, Eun‐Seok , Seok, Jin Myoung , Park, Jae Hong , Sekijima, Yoshiki , Kato, Naga-aki, Hineno, Akiyo , Kodaira, Minori , Yoshinaga, Tsuneaki , Takasone, Ken, Miyahara, Teruyoshi, Takahashi, Yusuke , Matsumoto, Kazuhiko , Lin, Kon-Ping, Lee, Yi‐Chung , Wixner, Jonas, Pilebro, Björn, Nordh, Erik, Chermenina, Maria, Nygren, Anneli, Tournev, Ivaylo, Zhelyazkova, Sashka , Cherneva, Zheyna , Sarafov, S., Cherninkova-Gopina, Sylvia, Vorona, Elena, Huesing-Kabar, Anna, Schilling, Matthias , Kabar, Iyad , Martinez–Naharro, Ana , Chacko, Liza , Cohen, Oliver , Law, Steven , Rezk, Tamer , Quan, Dianna , Dixon, Stacy, Fridman, Vera , Low, Soon-Chai , Mezei, Michelle M. , Jack, Kristin, Wade, N. Kevin, Lopate, Glenn, Geisler, Stephanie , Sommerville, R. Brian, Florence, Julaine, Stewart, Graeme J., Taylor, Mark , Suan, Daniel, Dingli, David , Gillmore, Julian D , Lee, Yi-Chung , Karamursel, Sacit , Adams, David , Berk, John L. , Conceição, Isabel , Dispenzieri, Angela , Peltier, Amanda , Bender, Shaun , Capocelli, Kelley, Obici, Laura , group, patisiran Global OLE study, Vita, Giuseppe, Russo, Massimo , Mazzeo, Anna Teresa , Gentile, Luca, Kaku, Michelle C. , Lau, Vincent, Dalton, James, May, John, Attarian, Shahram , Verschueren, Annie , Campana-Salort, Emmanuelle, Neves, Carlos, Santos, Miguel Oliveira , Coelho, Teresa, Correia, Nuno, Perez, Javier M, Silva, Ana Martins da, Ramalho, Joana, Yamasaki, Masahiro , Morimoto, Yuko, Tard, Céline , Hachulla, É. , Lebellec, Loïc , Théaudin, Marie , Al‐Salameh, Abdallah , Algalarrondo, Vincent , Rousseau, Antoine , Planté‐Bordeneuve, Violaine , Ayache, Samar S. , Corvoisier, Philippe Le , Waters, Michael, Manos, Paul, Lozza, Alessandro , Merlini, Giampaolo , Rosti, Vittorio , Sabatelli, Mario , Bisogni, Giulia , Luigetti, Marco , Romano, Ângela , Nienhuis, Hans L. A. , Neshige, Shuichiro , Horga, Alejandro , Feijoo, Julián García, Marques, Wilson , López, Inés AL, Sanz, Monica, Martinez, Jose M Gamez, Waddington‐Cruz, Márcia , Abreu, Aline Souza de, Silva, Moises Dias da, Pinto, Marcus Vinícius , Pinto, Luiz Felipe , Barroso, Fábio , Briseno, Maria Alejandra Gonzalez Duarte, Cárdenas‐Soto, Karla , Cantú-Brito, Carlos Gerardo , Şahin, Erdi , Çakar, Arman , İNAN, NERMİN GÖRKEM ŞİRİN, Polydefkis, Michael, Jarrett, Raquel, Singh, Mandeep , Judge, Daniel P. , Lui, Alvin T, Vista, Geno, Shimomura, Masahiro, Scheid, Christof , Holtick, Udo , Oh, Jeeyoung , Kim, Hee Jin, Shin, Hyun Jin , Choi, Kyomin , Mauricio, Elizabeth A. , Cooper, Leslie T. , Gonsalves, Wilson I. , Witzig, Thomas E. , Lin, Yi , Rajkumar, S. Vincent , Gertz, Morie A. , Chao, Chi‐Chao , Lee, Ming‐Jen , Hsieh, Sung‐Tsang , Tsai, Li‐Kai , Yeh, Shin‐Joe , Yang, Chih‐Chao , Lee, Ga-Yeon , Cho, Eun Bin , Min, Ju‐Hong , Lee, Hye Lim , Kishida, Dai , Imai, Akira, Lin, Kon‐Ping, Wixner, Jonas, Suhr, Ole B. , Anan, Intissar , Nordh, Erik, Domellöf, Fátima Pedrosa , Chamova, Teodora , Schmidt, Hartmut , Tepasse, Phil‐Robin , Gillmore, Julian D. , Lachmann, Helen J. , Goh, Khean Jin , Geisler, Stephanie, Taylor, Mark, Suan, Dan

Mayo Clinic

JAMA Neurology | January 13, 2025 | Volume: 82 | Issue: 3 | Pages: 228

10.1001/jamaneurol.2024.4631 | PMID 39804640 Get It

Importance There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN. Objective To present the long-term efficacy and safety of patisiran in adults with hATTR-PN. Design, Setting, and Participants This global open-label extension (OLE) of the APOLLO randomized clinical trial and phase 2 OLE study enrolled patients from 43 hospitals or clinical centers across 19 countries between July 2015 and August 2017, with follow-up until November 2022. Of 212 eligible patients with hATTR who completed the phase 3 APOLLO or phase 2 OLE parent studies, 211 enrolled in and 138 completed the global OLE. Intervention Patisiran, 0.3 mg/kg, intravenously once every 3 weeks for up to 5 years. Main Outcomes and Measures Outcomes evaluated at year 5 of the global OLE included disability (polyneuropathy disability [PND] score); polyneuropathy severity (Neuropathy Impairment Score [NIS]), nutritional status (modified body mass index [mBMI]), quality of life (Norfolk Quality of Life–Diabetic Neuropathy [Norfolk QOL-DN]), and Rasch-Built Overall Disability Scale (R-ODS), with no statistical hierarchy. Safety, survival probability, and mortality were also assessed. Results At the global OLE baseline, the mean (SD) age was 61.3 (12.3) years, and 156 patients (73.9%) were male. In 138 patients completing the study, PND scores remained stable or improved in 89 patients (65.0%), NISs showed a mean (SD) change of 10.9 (14.7), and mean (SD) mBMI (calculated as weight in kilograms divided by height in meters squared times serum albumin in grams per liter) increased by 46.4 (120.7) over 5 years from baseline. Norfolk QOL-DN and R-ODS scores showed mean (SD) changes of 4.1 (16.7) and –3.7 (6.2), respectively. Adverse events (AEs) leading to study withdrawal occurred in 47 patients (22.3%). Infusion-related reactions were the most common treatment-related AE (n = 34 [16.1%]). Overall, 41 patients (19.4%) died during the study. Patisiran treatment in the parent study and low familial amyloid polyneuropathy score at parent study baseline were associated with significantly improved survival. Conclusions and Relevance In the longest study of an RNAi therapeutic for any disease, patisiran treatment resulted in modest changes for patients with hATTR-PN with an acceptable safety profile. These results highlight the importance of initiating early treatment for hATTR and the potential of RNAi therapeutics in medicine. Trial Registration ClinicalTrials.gov Identifier: NCT02510261
Evolving trends in novel sleep tracking and sleep testing technology publications between 2020 and 2022
Schutte-Rodin, Sharon, Ratnasoma, Dulip, Baron, Kelly Glazer , Deak, Maryann C., Jerkins, Evin, Baughn, Julie , Gipson, Kevin S. , Miller, Jennifer N. , Paruthi, Shalini, Shah, Sachin, Bandyopadhyay, Anuja , Holfinger, Steven , Chiang, Ambrose , Gruber, Reut , Shah, Sachin

Mayo Clinic

Journal of Clinical Sleep Medicine | January 10, 2025 | Volume: 21 | Issue: 5 | Pages: 891-905

10.5664/jcsm.11562 | PMID 39789983 Get It

Predicting cognitive decline from neuropsychiatric symptoms and Alzheimer's disease biomarkers: A machine learning approach to a population-based data
Shah, Jay , Forzani, Erica , Jack, Cliff R, Petersen, Ronald C. , Che, Yiming , Wu, Teresa , Geda, Yonas E. , Krell-Roesch, Janina, Wu, Teresa , Geda, Yonas E , Krell‐Roesch, Janina , Knopman, David S.

Mayo Clinic

Journal of Alzheimer’s Disease | January 10, 2025 | Volume: 103 | Issue: 3 | Pages: 833-843

10.1177/13872877241306654 | PMID 39791216 Get It

Background The aim of this study was to examine the potential added value of including neuropsychiatric symptoms (NPS) in machine learning (ML) models, along with demographic features and Alzheimer's disease (AD) biomarkers, to predict decline or non-decline in global and domain-specific cognitive scores among community-dwelling older adults. Objective To evaluate the impact of adding NPS to AD biomarkers on ML model accuracy in predicting cognitive decline among older adults. Methods The study was conducted in the setting of the Mayo Clinic Study of Aging, including participants aged ≥ 50 years with information on demographics (i.e., age, sex, education), NPS (i.e., Neuropsychiatric Inventory Questionnaire; Beck Depression and Anxiety Inventories), at least one AD biomarker (i.e., plasma-, neuroimaging- and/or cerebrospinal fluid [CSF]-derived), and at least 2 repeated neuropsychological assessments. We trained and tested ML models using a stepwise feature addition approach to predict decline versus non-decline in global and domain-specific (i.e., memory, language, visuospatial, and attention/executive function) cognitive scores. Results ML models had better performance when NPS were included along with a) neuroimaging biomarkers for predicting decline in global cognition, as well as language and visuospatial skills; b) plasma-derived biomarkers for predicting decline in visuospatial skills; and c) CSF-derived biomarkers for predicting decline in attention/executive function, language, and memory. Conclusions NPS, added to ML models including demographic and AD biomarker data, improves prediction of downward trajectories in global and domain-specific cognitive scores among community-dwelling older adults, albeit effect sizes are small. These preliminary findings need to be confirmed by future cohort studies.
Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta, Shruti , Kaunfer, Sarah Allison , Chen, Kevin L. , Dias, Julie‐Alexia , Rajasekaran, Arun , Prosek, Jason, Truong, Huong L. , Wood, Anthony C., Bassil, Claude , Renaghan, Amanda D., Carlos, Christopher A., Kelly, Katherine J. , Passero, Christopher J., Abudayyeh, Ala , Shin, Daniel Sanghoon , Yelvington, Bradley, Kanduri, Swetha Rani , Neyra, Javier A. , Shirali, Anushree C. , Bansal, Anip, Geara, Abdallah Sassine , Mithani, Zain, Ziolkowski, Susan , Rashidi, Arash, Jakubowski, Jonathan, Pujari, Ashwini, Dotson, Emily, Wall, Sarah , Patton, John T. , Barreto, Jason N. , Sheikh, M. Salman , Lee, Jamie, Lucchesi, Nicholas, Kolman, Michael David, Rasheed, Muhammad Ahsan, Afzal, Afsheen, Mahesh, Amrita, Hsu, Raymond K. , Nicolaysen, Anthony, Tefera, Kibrewessen, Schretlen, Claire F. , Miller, Ryan M. , Velez, Juan Carlos Q. , Chandrasekhara, Soniya, Donley, Vicki, Patel, Ashka , Krishnamurthy, Shobana, Ali, Rafia, Yilmam, Osman A , Wells, Sophia L., Ortega, Jessica L. , Green‐Lingren, Olivia, Leaf, Rebecca Karp , Sise, Meghan E. , Nayak, Lakshmi , LaCasce, Ann S. , Leaf, David E. , Kaunfer, Sarah A , Rajasekaran, Arun , Shah, Chintan V , Glezerman, Ilya G , Kelly, Katherine , Abudayyeh, Ala , Neyra, Javier A , Edmonston, Daniel , Ziolkowski, Susan L , Bond, David A , Patton, John , Barreto, Jason N , Herrmann, Sandra M , Sheikh, Mohammad S , Hsu, Raymond K , Aklilu, Abinet M , Krishnamurthy, Shobana , Yilmam, Osman A , Ortega, Jessica L , LaCasce, Ann Steward , Leung, Nelson , Leaf, David E , Gupta, Shruti , Dias, Julie-Alexia , Vijayan, Anitha , Zhang, Jingjing , Drappatz, Jan , Sperati, Christopher John , Rashidi, Arash , Bond, David A. , Patton, John T. , Herrmann, Sandra M. , Baz, Rachid , Lee, Jamie, Kolman, M F , Afzal, Afsheen, Kang, Dasol, Mahesh, Amrita, Miller, Ryan M., Flannery, Alexander H , Aklilu, Abinet M. , Anand, Shuchi , Ni, Jian, Wells, Sophia L., Leung, Nelson

Mayo Clinic

Blood | January 6, 2025 | Volume: 145 | Issue: 17 | Pages: 1858-1869

10.1182/blood.2024026211 | PMID 39760780 Get It

Abstract High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the United States using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine &lt;1.5-fold baseline and without dialysis dependence. Key secondary end points were time to kidney recovery, neutropenia, and transaminitis on day 7, and time to death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% confidence interval [CI], 1.69–4.31) compared with no glucarpidase receipt. Patients treated with glucarpidase also had faster time to kidney recovery (adjusted hazard ratio [aHR], 1.88; 95% CI, 1.18–3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50; 95% CI, 0.28–0.91) and grade ≥2 transaminitis (aOR, 0.50; 95% CI, 0.28–0.91) on day 7. There was no difference in time to death (aHR, 0.76; 95% CI, 0.49–1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.
Updated Geriatrics Competencies for Graduating Medical Students: Training Physicians to Provide Age-Friendly Care
Schwartz, Andrea Wershof , Sehgal, Mandi , Dawson, Catherine M. P. , Granville, Lisa , Powers, Becky , Shah, Amit , Sullivan, Amy , Leipzig, Rosanne M. , Powers, Becky B , Shah, Amit A , Sullivan, Amy M , Schwartz, Andrea Wershof

Mayo Clinic

Academic Medicine | January 3, 2025 | Volume: 100 | Issue: 5 | Pages: 592-599

10.1097/acm.0000000000005958 | PMID 39752580 Get It

Abstract Purpose Medical student education in geriatrics is a critical need for every doctor-in-training as the population ages, with fewer than 7,000 geriatricians, and older patients, who now approach 20% of the U.S. population, having unique health care needs. This study presents the updated competencies in geriatrics for graduating medical students, framed by the Geriatrics 5Ms (Mind, Mobility, Medications, Multicomplexity, and What Matters Most). Method From 2019–2022, a working group of the American Geriatrics Society (AGS) drafted the updated medical student geriatrics education competencies, using a modified Delphi approach. The working group reviewed the literature, conducted an initial survey of working group members, and drafted and refined proposed updates to the competencies. The 27 resulting competencies were disseminated as a national survey to geriatrics experts and medical school education deans. Following the national survey, the competencies were updated and presented at the 2021 AGS Annual Scientific Meeting and open to public comment before they were finalized. Results The 27 updated geriatrics competencies for medical students included several new competencies, such as a focus on health equity, frailty, deprescribing, and patient priorities. A total of 211 respondents completed the national survey, including geriatrics experts (187/398, response rate: 47.0%) and education deans (24/191, response rate: 12.6%). All 27 proposed competencies met the predetermined threshold of 70% cumulative agreement, with a range of 93.0% (174/187) to 100% (187/187) among geriatrics experts and 87.5% (21/24) to 100% (24/24) among education deans. Conclusions The updated Geriatrics Competencies for Graduating Medical Students met with broad agreement among the geriatrics experts and medical school education deans who responded to the national survey. By focusing on the Geriatrics 5Ms, the competencies highlight key knowledge and skills graduating medical students need for the first day of internship to be prepared to deliver age-friendly care to older adults under their care.
Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON‐HF
Lu, Henri , Inciardi, Riccardo M. , Abanda, Martin Hongieh , Shah, Amil M. , Čikeš, Maja , Claggett, Brian , Prasad, Narayana , Lam, Carolyn S.P. , Redfield, Margaret M. , McMurray, John J.V. , Solomon, Scott D. , Abanda, Martin , Claggett, Brian L , Redfield, Margaret M , Pfeffer, Marc Alan , Solomon, Scott David , Hegde, Sheila M , Skali, Hicham , McMurray, John J V , Lam, Carolyn S P , Shah, Amil , Hegde, Sheila M. , Skali, Hicham

Mayo Clinic

Journal of the American Heart Association | December 24, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/jaha.124.037380 | PMID 39719412 Get It

Background This study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with preserved ejection fraction. Methods and Results Data from 809 patients in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin‐Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction) echocardiographic substudy (55% women, mean age 74±8 years) were analyzed. Correlates of RVD (defined as tricuspid annular plane systolic excursion <1.7 cm, fractional area change <35% or absolute RV free wall longitudinal strain <20%) were identified using multivariable logistic regression models. We further assessed the prognostic value of the number of abnormal RV parameters (0, 1, ≥2) on total HF hospitalizations (HFH) and cardiovascular death, total HFH, first HFH or cardiovascular death, all‐cause death, and cardiovascular death. RVD was identified in 461 (57%) patients. Correlates of RVD included older age, higher heart rate, atrial fibrillation/flutter, greater left ventricle wall thickness, higher N‐terminal pro‐B‐type natriuretic peptide levels, lower systolic blood pressure, and lower left ventricle absolute global longitudinal strain. These results were consistent across sexes, except atrial fibrillation/flutter and LV wall thickness, which were associated with a higher risk of RVD in men but not in women. Participants with ≥2 abnormal RV parameters had a significantly higher adjusted risk of total HFH and cardiovascular death (rate ratio, 2.13 [95% CI, 1.13–4.01]), first HFH or cardiovascular death, all‐cause death, and cardiovascular death. Conversely, an isolated abnormal RV parameter was not associated with a worse outcome. Conclusions RV measures may underestimate the burden of RVD in HF with preserved ejection fraction when considered in isolation. Clinicians should consider multiple dimensions to comprehensively assess RV function in patients with HF with preserved ejection fraction.
Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF
Ambrosy, Andrew P. , Patel, Shachi, Windsor, Sheryl L. , Husain, Mansoor, Inzucchi, Silvio E. , Kitzman, Dalane W, Kosiborod, Mikhail , Sauer, Andrew J , Borlaug, Barry A. , Kitzman, Dalane W. , McGuire, Darren K. , Shah, Sanjiv J , Sharma, Kavita, Umpierrez, Guillermo E.

Mayo Clinic

ESC Heart Failure | December 24, 2024 | Volume: 12 | Issue: 3 | Pages: 1676-1681

10.1002/ehf2.15184 | PMID 39716939 Get It

Abstract Aims Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of dapagliflozin on health status vary based on estimated glomerular filtration rate (eGFR). Methods and Results We conducted a pooled participant-level analysis of two double-blind, randomized trials, DEFINE-HF (n = 236) and PRESERVED-HF (n = 324), which evaluated dapagliflozin versus placebo. Both multicentre studies enrolled adults with HF, New York Heart Association Class II or higher, elevated natriuretic peptides, and an EF &lt; 40% in DEFINE-HF or &gt;45% in PRESERVED-HF. The primary exposure was eGFR. The main outcome was the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 12 weeks. Across both trials, there were 583 (99.3%) participants with a baseline eGFR. The median (25th, 75th) eGFR was 59 (46, 77) mL/min/1.73 m2. Dapagliflozin improved KCCQ-CSS at 12 weeks [placebo-adjusted difference, +5.0 points, 95% confidence interval (CI) 2.6–7.5; P &lt; 0.001], and this was consistent in participants with an eGFR ≥ 60 (+6.0 points, 95% CI 2.4–9.7; P = 0.001) and eGFR &lt; 60 (+4.1 points, 95% CI 0.5–7.7; P = 0.025) (P interaction = 0.46). The benefits of dapagliflozin on KCCQ-CSS remained robust across eGFR when modelled as a continuous variable (P interaction = 0.48). Conclusions Dapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.